<DOC>
	<DOCNO>NCT00270582</DOCNO>
	<brief_summary>Primary evaluate 1-year treatment failure rate two sequential chemotherapy regimen : 1. weekly docetaxel plus cisplatin follow gemcitabine 2. gemcitabine plus cisplatin follow weekly docetaxel . Study design : Prospective , multi-center , open-labelled , randomized phase II study .</brief_summary>
	<brief_title>A Study Weekly Docetaxel Plus Cisplatin Followed Gemcitabine vs. Gemcitabine Plus Cisplatin Followed Weekly Docetaxel Treatment Advanced Non-Small-Cell Lung Cancer</brief_title>
	<detailed_description>Lung cancer lead cause cancer death men woman worldwide . Shifting trend incidence lung cancer closely follow pattern cigarette smoking , although carcinogen implicate . Despite intensive past several decade , 5-yr lung-cancer survival rate remain dismal 8-14 % . Although lung cancer common cancer , lead cause cancer-related death men woman , deadly ( American Cancer Society 2000 ) . Lung cancer also lead cause cancer death Taiwan . According vital statistic Department Health Taiwan , incidence lung cancer rank 5th . However , rank cancer fatality second first men woman , respectively . The mortality lung cancer significant increase trend men woman two-decade period . There 6,555 person die lung cancer 2001 . There 25 % case resectable diagnose 15~18 % case surgical remove . The postoperative recurrence rate metastasis rate also high NSCLC . Chemotherapy use primarily palliate disease symptom prolong survival patient unresectable disease ( stage IIIB IV ) . However , overall survival benefit modest . Gemcitabine show good activity NSCLC , single agent combination various cytotoxic drug ( Eli Lilly Company 1999 ) . A number phase I II study NSCLC show good safety efficacy two-drug combination Gemcitabine agent cisplatin , include carboplatin , paclitaxel , vinorelbine , docetaxel ( Eli Lilly Company 1999 ) . Gemcitabine plus cisplatin ( GC ) one active regimen treatment fir stage IIIB/IV NSCLC patient . In phase II study , 26-54 % stage IIIB/IV NSCLC patient respond GC treatment . Good median 1-year survival consistently observe ( Abratt et al , 1997 ; Crino et al , 1997 ; Einhorn , 1997 ; Shepherd et al , 1997 ) In randomized phase III study , GC demonstrate superior survival versus cisplatin alone ( Sandler A et al . 2000 ) , significantly high response rate versus three-drug combination cisplatin , mitomycin C ifosfamideb ( Crino L et al . 1999 ) . Schiller JH et al . conduct randomized study determine whether three chemotherapy regimens superior cisplatin paclitaxel patient advance non-small-cell lung cancer ( Schiller JH et al . 2000 ) . Patients advance non-small-cell lung cancer randomly assign reference regimen cisplatin paclitaxel one three experimental regimen : cisplatin gemcitabine , cisplatin docetaxel , carboplatin paclitaxel . However , none four chemotherapy regimen offer significant advantage others treatment advance non-small-cell lung cancer . GC provide long time progression three regimen . Abratt et al ( 1997 ) use GC stage IIIB/IV patient deliver cisplatin day 15 result goodresponse rate ( 52 % ) , median survival ( 13 month ) associate low haematological toxicity dose modification either gemicitabine ciplatin . This schedule seem feasible induction treatment . Docetaxel plus cisplatin one option front line treatment . TAX326- phase III trial study docetaxel + cisplatin carboplatin v vinorelbine/cisplatin ( VC ) first-line therapy advance non-small cell lung cancer ( NSCLC ) . The schedule chemotherapy 75 mg/m² docetaxel follow 75 mg/m² cisplatin repeat every 3 week Vinorelbine 25 mg/m2 IV day 1 , 8 , 15 , 22 Cisplatin 100 mg/m2 IV day 1 every 4 week . The overall response rate 32 % ( docetaxel+cisplatin ) 25 % ( VC ) . Docetaxel plus cisplatin show survival benefit compare VC ( 1-year survival rate : 46 % v.s . 41 % ) . Several phase II trial investigate efficacy safety Gemcitabine single agent , second-line therapy . Table summarizes result phase II trials.These trial conclude gemcitabine modest activity second-line chemotherapy NSCLC . It advantage well tolerate may thus one drug propose patient disease progression first-line chemotherapy ask treatment . In initial development docetaxel paclitaxel , drug routinely administer every 3 week . However , weekly administration agent appear offer several advantage term toxicity . Both agent administer weekly markedly decreased myelosuppression , maintain increase dose intensity ( Fennelly D et al 1997 ; Seidman AD et al 1998 ; Hainsworth JD et al 1998 ) . A Phase I trial demonstrate docetaxel could administer weekly maximum tolerate dose 43 mg/m2/week , fatigue asthenia dose-limiting toxicity ( Hainsworth JD et al 1998 ) . At weekly dose 36 mg/m2 , docetaxel extremely well tolerate , significant myelosuppression occasional NCIC-CTG Grade 3 4 non-hematologic toxicity . The recommend dose 36 mg/m2 . Four clinical study single-agent weekly docetaxel patient NSCLC report . As second-line therapy NSCLC , weekly docetaxel study 3 group ( Baylor-Charles 2000 ; Serke M et al 2001 ; Garcia-Lopez JL et al 2000 ) , Hainsworth JD colleague study weekly docetaxel first-line treatment NSCLC ( Hainsworth JD et al 2000 ) . The 3 study weekly docetaxel single agent , second-line consistently demonstrate efficacy similar toxicity profile . Objective response rate range 11 % 26.7 % , percentage patient respond maintain stable disease range 37.5 % 66.7 % . Docetaxel generally well tolerate study . Weekly docetaxel study combination commonly use NSCLC chemotherapeutic agent include carboplatin , navelbine , gemcitabine . These combination study first- second-line setting . Second line chemotherapy docetaxel may affect survival ( TAX 318 , 1 year survival 37 % vs. 11 % ) . However , optimal sequence chemotherapy rarely explore . Weekly docetaxel may offer good tolerability vs. 3-weekly schedule combine docetaxel cisplatin . Based upon study , choose weekly docetaxel combination cisplatin regimen . We expect regimen would effective well tolerate . Based data , study propose compare efficacy safety two regimen ( weekly docetaxel plus cisplatin follow gemcitabine vs. gemcitabine plus cisplatin follow weekly docetaxel ) metastatic locally advanced non-small cell lung cancer .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1.Written informed consent prior begin specific protocol procedure include expected cooperation patient treatment followup , must obtain document accord local regulatory requirement . 2 . Histologically cytologically proven nonsmall cell lung carcinoma . 3 . Stage IIIB IV disease , curative treatment available , candidate chemotherapy . 4 . Age &gt; 18 year &lt; 75 year . 5 . Performance status WHO performance status 0,1 . 6 . Previous therapy : ( ) Chemotherapy : None . ( b ) Previous radiation therapy : prior irradiation NSCLC permit , however , measurable evaluable nonmeasurable disease must completely outside radiation portal . 7 . Unidimentional bidimentional measurable disease . 8 . Life expectancy &gt; 12 week . 9 . Laboratory requirement : 1 . Hematology : Neutrophils * 1.5 109/l , Platelets * 100 109/l , Hemoglobin &gt; 10 g/dl . 2 . Hepatic function : Total bilirubin &lt; 1.5 UNL , ASAT ( SGOT ) ALAT ( SGPT ) &lt; 2.5 UNL , Alkaline phosphatases &lt; 5 UNL ; except presence bone metastasis absence liver disorder . Patients ASAT and/or ALAT &gt; 1.5 x UNL associate alkaline phosphatase &gt; 2.5 x UNL eligible study . 3 . Renal function : Creatinine &lt; 1 UNL , creatinine clearance &gt; 60 ml/min . 10.Complete initial lab study within 2 week prior first infusion , image study within 4 week prior first infusion . 11.Patients must accessible treatment followup . 1.Pregnant , lactate patient ; patient childbearing potential must implement adequate contraceptive measure study participation . 2 . Symptomatic central nervous system metastasis , patient asymptomatic brain metastasis accept tumor irradiate need steroid control symptom . 3 . Preexisting motor sensory neurotoxicity severity &gt; grade 1 NCICCTG criterion . 4 . Other serious illness medical condition : 1. congestive heart failure unstable angina pectoris . High risk uncontrolled arrhythmia . 2. history significant neurological psychiatric disorder include psychotic disorder , dementia seizure would prohibit understanding give informed consent . 3. active uncontrolled infection . 4. contraindication use corticosteroid . 5 . Past current history neoplasm non small cell lung cancer , except curatively treat non melanoma skin cancer , situ carcinoma cervix within 5 year . 6 . Concurrent treatment experimental drug . Participation another clinical trial investigational drug within 30 day prior study entry . 7 . Concurrent treatment anticancer therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>